Physician profile
Sharon Prior
NPI 1073183935
$16,268.39
in general payments reported to CMS, 2019-2025
28 companies · $2,822 in 2025
The $2,822 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,512 · 2022: $3,643 · 2023: $4,485 · 2024: $3,807 · 2025: $2,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,114.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,109.55 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,024.72 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,895.97 | 2021-2025 | |
| Alkermes, INC. | $1,500.95 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,101.82 | 2021-2025 | Spravato |
| Axsome Therapeutics, INC. | $991.67 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $989.12 | 2021-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $955.46 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $902.70 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $758.24 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $510.33 | 2021-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $361.44 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $325.09 | 2021-2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $297.65 | 2021-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $288.55 | 2022-2025 | Qelbree, Qelbree |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $236.05 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $213.08 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $212.57 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $150.11 | 2024 | Cobenfy |
| Neurelis, INC. | $118.53 | 2021 | |
| Biogen, INC. | $75.92 | 2022-2025 | Zurzuvae |
| Indivior INC. | $63.89 | 2022-2023 | Sublocade |
| Noven Therapeutics, LLC | $54.60 | 2024 | Xelstrym, Secuado |
| Alfasigma USA, INC. | $44.28 | 2022 | |
| Luye Pharma (USA) LTD. | $30.07 | 2025 | Erzofri Extended-Release |
| Merck Sharp & Dohme LLC | $21.56 | 2023 | Belsomra |
| Neos Therapeutics, LP | $17.34 | 2024 | Adzenys Xr-Odt |
| Acadia Pharmaceuticals INC | $17.13 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Prior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.